$INGN
Inogen Inc Stock $ingn

$ingn Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024023820 Filed on March 01, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$78.03M	$75.90M	$315.7M
YoY Change	8.12%	-13.84%	-16.32%
Cost Of Revenue	$43.65M	$47.74M	$189.0M
YoY Change	5.37%	-18.56%	-15.53%
Gross Profit	$34.37M	$28.16M	$126.7M
YoY Change	11.84%	-4.46%	-17.48%
Gross Profit Margin	44.05%	37.1%	40.14%
Selling, General & Admin	$44.07M	$50.43M	$182.4M
YoY Change	-6.84%	68.85%	10.74%
% of Gross Profit	128.21%	179.08%	143.92%
Research & Development	$6.578M	$6.714M	$20.84M
YoY Change	23.09%	13.14%	-5.03%
% of Gross Profit	19.14%	23.84%	16.45%
Depreciation & Amortization	$5.265M	$5.144M	$18.15M
YoY Change	28.85%	-13.95%	-22.8%
% of Gross Profit	15.32%	18.27%	14.33%
Operating Expenses	$50.65M	$57.14M	$236.1M
YoY Change	-3.8%	59.61%	-1.13%
Operating Profit	-$16.27M	-$28.98M	-$109.4M
YoY Change	-25.74%	358.0%	28.32%
Interest Expense	$1.403M	$1.602M	$6.574M
YoY Change	-8.0%	-6.59%	131.72%
% of Operating Profit
Other Income/Expense, Net	$1.546M	$292.0K	$7.042M
YoY Change	-12.26%	-4.26%	256.56%
Pretax Income	-$14.73M	-$27.09M	-$102.3M
YoY Change	-26.92%	-52.03%	22.91%
Income Tax	-$150.0K	-$533.0K	$105.0K
% Of Pretax Income
Net Earnings	-$14.58M	-$26.56M	-$102.4M
YoY Change	-28.36%	-53.09%	22.3%
Net Earnings / Revenue	-18.68%	-34.99%	-32.46%
Basic Earnings Per Share	-$0.62		-$4.42
Diluted Earnings Per Share	-$0.62	-$1.14	-$4.42
COMMON SHARES
Basic Shares Outstanding	23.33M	23.31M	23.18M
Diluted Shares Outstanding	23.40M		23.18M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$119.8M	$128.5M	$128.5M
YoY Change	-31.37%	-31.3%	-31.3%
Cash & Equivalents	$107.4M	$125.5M	$125.5M
Short-Term Investments	$12.36M	$2.979M	$2.979M
Other Short-Term Assets	$13.59M	$13.85M	$13.85M
YoY Change	-3.05%	-27.84%	-27.84%
Inventory	$24.60M	$21.84M	$21.84M
Prepaid Expenses
Receivables	$40.22M	$42.24M	$42.24M
Other Receivables	$976.0K	$669.0K	$669.0K
Total Short-Term Assets	$199.2M	$207.1M	$207.1M
YoY Change	-29.65%	-32.03%	-32.03%
LONG-TERM ASSETS
Property, Plant & Equipment	$49.27M	$50.32M	$70.65M
YoY Change	7.24%	16.29%	8.83%
Goodwill	$9.834M	$10.06M
YoY Change	-70.1%	-69.39%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.819M	$3.825M	$3.825M
YoY Change	47.45%	56.44%	56.44%
Total Long-Term Assets	$116.4M	$119.1M	$119.1M
YoY Change	13.54%	18.66%	18.66%
TOTAL ASSETS
Total Short-Term Assets	$199.2M	$207.1M	$207.1M
Total Long-Term Assets	$116.4M	$119.1M	$119.1M
Total Assets	$315.6M	$326.2M	$326.2M
YoY Change	-18.17%	-19.47%	-19.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$15.92M	$13.45M	$23.51M
YoY Change	-11.76%	-26.23%	-19.14%
Accrued Expenses	$20.54M	$21.35M	$21.35M
YoY Change	3.86%	8.92%	8.92%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$73.91M	$72.50M	$72.50M
YoY Change	16.62%	10.94%	10.94%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$41.64M	$40.35M	$40.35M
YoY Change	1.57%	-4.59%	-4.59%
Total Long-Term Liabilities	$41.64M	$40.35M	$40.35M
YoY Change	1.57%	-4.59%	-4.59%
TOTAL LIABILITIES
Total Short-Term Liabilities	$73.91M	$72.50M	$72.50M
Total Long-Term Liabilities	$41.64M	$40.35M	$40.35M
Total Liabilities	$123.7M	$121.4M	$121.4M
YoY Change	18.51%	12.77%	12.77%
SHAREHOLDERS EQUITY
Retained Earnings	-$131.5M	-$116.9M
YoY Change	277.42%	706.54%
Common Stock	$323.2M	$320.5M
YoY Change	2.24%	2.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$191.9M	$204.8M	$204.8M
YoY Change
Total Liabilities & Shareholders Equity	$315.6M	$326.2M	$326.2M
YoY Change	-18.17%	-19.47%	-19.47%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$14.58M	-$26.56M	-$102.4M
YoY Change	-28.36%	-53.09%	22.3%
Depreciation, Depletion And Amortization	$5.265M	$5.144M	$18.15M
YoY Change	28.85%	-13.95%	-22.8%
Cash From Operating Activities	-$4.749M	-$3.148M	-$3.234M
YoY Change	-24.63%	-79.67%	-91.38%
INVESTING ACTIVITIES
Capital Expenditures	$1.310M	$6.302M	$5.218M
YoY Change	21.75%	-11.64%	56.37%
Acquisitions			$29.63M
YoY Change
Other Investing Activities	-$9.314M	$10.43M	-$32.30M
YoY Change	-9.58%	5447.87%	-412.27%
Cash From Investing Activities	-$13.44M	$4.128M	-$59.32M
YoY Change	-21.43%	-159.45%	445.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	285.0K	-14.00K	960.0K
YoY Change	-49.02%	-87.5%	152.63%
NET CHANGE
Cash From Operating Activities	-4.749M	-3.148M	-3.234M
Cash From Investing Activities	-13.44M	4.128M	-59.32M
Cash From Financing Activities	285.0K	-14.00K	960.0K
Net Change In Cash	-18.05M	966.0K	-61.52M
YoY Change	-21.11%	-104.29%	26.82%
FREE CASH FLOW
Cash From Operating Activities	-$4.749M	-$3.148M	-$3.234M
Capital Expenditures	$1.310M	$6.302M	$5.218M
Free Cash Flow	-$6.059M	-$9.450M	-$8.452M
YoY Change	-17.87%	-58.21%	-79.32%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grant In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodFairValue	0
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001294133
CY2021	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grant In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodFairValue	0
CY2022	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grant In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodFairValue	0
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Property Plant And Equipment Useful Life Description Of Term Extensible Enumeration PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration	http://fasb.org/us-gaap/2023#LeaseholdImprovementsMember
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-36309
CY2023	dei	Entity Registrant Name EntityRegistrantName	INOGEN, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	33-0989359
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	43269000
CY2023Q4	us-gaap	Goodwill Goodwill	10057000
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	859 Ward Drive
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Goleta
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	93111
CY2023	dei	City Area Code CityAreaCode	(805)
CY2023	dei	Local Phone Number LocalPhoneNumber	562-0500
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2023	dei	Trading Symbol TradingSymbol	INGN
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	267900000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23326783
CY2023	dei	Auditor Firm AuditorFirmId	34
CY2023	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2023	dei	Auditor Location AuditorLocation	Los Angeles, California, USA
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	125492000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	187014000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	2979000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	42241000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	62725000
CY2023Q4	us-gaap	Inventory Net InventoryNet	21840000
CY2022Q4	us-gaap	Inventory Net InventoryNet	34093000
CY2023Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	669000
CY2022Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	1626000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13846000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19187000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	207067000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	304645000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	50316000
CY2022Q4	us-gaap	Goodwill Goodwill	32852000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	34591000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	177000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20338000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	21653000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3825000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2445000
CY2023Q4	us-gaap	Assets Assets	326194000
CY2022Q4	us-gaap	Assets Assets	405041000
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	30142000
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	33974000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11066000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11190000
CY2023Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	9628000
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	7790000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3653000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3515000
CY2023Q4	ingn	Earnout Liability EarnoutLiability	10000000
CY2023Q4	ingn	Contract With Customer Liability And Lease Deferred Revenue Current ContractWithCustomerLiabilityAndLeaseDeferredRevenueCurrent	7980000
CY2022Q4	ingn	Contract With Customer Liability And Lease Deferred Revenue Current ContractWithCustomerLiabilityAndLeaseDeferredRevenueCurrent	8880000
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	27000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	72496000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	65349000
CY2023Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	13850000
CY2022Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	12123000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	18270000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	19764000
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	8227000
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	10399000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	8539000
CY2023Q4	us-gaap	Liabilities Liabilities	121382000
CY2022Q4	us-gaap	Liabilities Liabilities	107635000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23324750
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23324750
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22941643
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22941643
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	23000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	23000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	320513000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	312126000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-116949000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-14500000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1225000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-243000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	204812000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	297406000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	326194000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	405041000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	251607000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	320549000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	311730000
CY2023	ingn	Rental Revenue Net RentalRevenueNet	64053000
CY2022	ingn	Rental Revenue Net RentalRevenueNet	56692000
CY2021	ingn	Rental Revenue Net RentalRevenueNet	46273000
CY2023	us-gaap	Revenues Revenues	315660000
CY2022	us-gaap	Revenues Revenues	377241000
CY2021	us-gaap	Revenues Revenues	358003000
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	158636000
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	197805000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	161824000
CY2023	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	12893000
CY2022	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	11103000
CY2021	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	8860000
CY2023	ingn	Cost Of Rental CostOfRental	30325000
CY2022	ingn	Cost Of Rental CostOfRental	25903000
CY2021	ingn	Cost Of Rental CostOfRental	19696000
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	188961000
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	223708000
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	181520000
CY2023	ingn	Gross Profit Sales Revenue GrossProfitSalesRevenue	92971000
CY2022	ingn	Gross Profit Sales Revenue GrossProfitSalesRevenue	122744000
CY2021	ingn	Gross Profit Sales Revenue GrossProfitSalesRevenue	149906000
CY2023	ingn	Gross Profit Rental Revenue GrossProfitRentalRevenue	33728000
CY2022	ingn	Gross Profit Rental Revenue GrossProfitRentalRevenue	30789000
CY2021	ingn	Gross Profit Rental Revenue GrossProfitRentalRevenue	26577000
CY2023	us-gaap	Gross Profit GrossProfit	126699000
CY2022	us-gaap	Gross Profit GrossProfit	153533000
CY2021	us-gaap	Gross Profit GrossProfit	176483000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20840000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21943000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16576000
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	107091000
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	120767000
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	112815000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	75260000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	43905000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	37852000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
CY2022	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-52161000
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	32894000
CY2023	us-gaap	Operating Expenses OperatingExpenses	236085000
CY2022	us-gaap	Operating Expenses OperatingExpenses	238776000
CY2021	us-gaap	Operating Expenses OperatingExpenses	167243000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-109386000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-85243000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	9240000
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	6574000
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	2837000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	129000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	468000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-862000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-710000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7042000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1975000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-581000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-102344000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-83268000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	8659000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	105000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	504000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	14992000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-102449000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-83772000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-6333000
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1358000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-597000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-800000
CY2022	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	-3130000
CY2021	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	1746000
CY2022	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	-1990000
CY2021	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	-47000
CY2022	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-1140000
CY2021	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	1793000
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	110000
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	25000
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1468000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1712000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	994000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-100981000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-85484000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5339000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.42
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.67
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.42
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.67
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23176098
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22852571
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22490027
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23176098
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22852571
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22490027
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	349623000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10943000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1948000
CY2021	ingn	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	412000
CY2021	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	235000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13699000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-6333000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	994000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	370227000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12283000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1691000
CY2022	ingn	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	1252000
CY2022	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	103000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	44000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-83772000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1712000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	297406000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7427000
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1094000
CY2023	ingn	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	517000
CY2023	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	1000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	384000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-102449000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1468000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	204812000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-102449000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-83772000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-6333000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	18152000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	23514000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	21628000
CY2023	ingn	Gain Loss On Write Off Of Rental Assets And Other Fixed Assets GainLossOnWriteOffOfRentalAssetsAndOtherFixedAssets	-4508000
CY2022	ingn	Gain Loss On Write Off Of Rental Assets And Other Fixed Assets GainLossOnWriteOffOfRentalAssetsAndOtherFixedAssets	-3095000
CY2021	ingn	Gain Loss On Write Off Of Rental Assets And Other Fixed Assets GainLossOnWriteOffOfRentalAssetsAndOtherFixedAssets	-1521000
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	84000
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	154000
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	65000
CY2023	ingn	Provision For Sales Returns And Doubtful Accounts ProvisionForSalesReturnsAndDoubtfulAccounts	10730000
CY2022	ingn	Provision For Sales Returns And Doubtful Accounts ProvisionForSalesReturnsAndDoubtfulAccounts	13024000
CY2021	ingn	Provision For Sales Returns And Doubtful Accounts ProvisionForSalesReturnsAndDoubtfulAccounts	11094000
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	2691000
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	2423000
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	2062000
CY2023	ingn	Loss On Purchase Commitments LossOnPurchaseCommitments	2057000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	7427000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	12283000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	10943000
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-251000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	14444000
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	6822000
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-15386000
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-11596000
CY2022	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-52161000
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	32894000
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-10141000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	51337000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6127000
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-7878000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5601000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	10775000
CY2023	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-988000
CY2022	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	281000
CY2021	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-705000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-5583000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-6803000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8104000
CY2023	ingn	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-3413000
CY2022	ingn	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-3259000
CY2021	ingn	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	16087000
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1110000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-224000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-96000
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-9177000
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6759000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6476000
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-508000
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-6106000
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	10231000
CY2023	ingn	Increase Decrease In Warranty Reserve IncreaseDecreaseInWarrantyReserve	3565000
CY2022	ingn	Increase Decrease In Warranty Reserve IncreaseDecreaseInWarrantyReserve	6187000
CY2021	ingn	Increase Decrease In Warranty Reserve IncreaseDecreaseInWarrantyReserve	-668000
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3075000
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1150000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	1613000
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	27000
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-82000
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-1141000
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3456000
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3395000
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	16668000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3234000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37532000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	23633000
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	26869000
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	9987000
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	24000000
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	10014000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	19256000
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	494000
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	132000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5218000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3337000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5482000
CY2023	ingn	Payments To Produce And Purchase Rental Equipment PaymentsToProduceAndPurchaseRentalEquipment	21299000
CY2022	ingn	Payments To Produce And Purchase Rental Equipment PaymentsToProduceAndPurchaseRentalEquipment	17885000
CY2021	ingn	Payments To Produce And Purchase Rental Equipment PaymentsToProduceAndPurchaseRentalEquipment	18453000
CY2023	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	198000
CY2022	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	331000
CY2021	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	153000
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	29633000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-59315000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10877000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14645000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	384000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	44000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	13699000
CY2023	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1094000
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1691000
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1948000
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	518000
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1355000
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	647000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	960000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	380000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15000000
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	67000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-481000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-426000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-61522000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-48510000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	23562000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	187014000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	235524000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	211962000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	125492000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	187014000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	235524000
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-703000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	499000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1544000
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	3178000
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	204000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	428000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	353000
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inogen, Inc. (Company or Inogen) was incorporated in Delaware on November 27, 2001. The Company is a medical technology business that primarily develops, manufactures, and markets innovative portable oxygen concentrators (POCs) used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Traditionally, these patients have relied on stationary oxygen concentrator systems for use in the home and oxygen tanks or cylinders for mobile use, which the Company refers to as the delivery model. The tanks and cylinders must be delivered regularly and have a finite amount of oxygen, which requires patients to plan activities outside of their homes around delivery schedules and a finite oxygen supply. Additionally, patients must attach long, cumbersome tubing to their stationary concentrators simply to enable mobility within their homes. The Company’s proprietary Inogen One® and Inogen Rove systems concentrate the air around the patient to offer a source of supplemental oxygen anytime, anywhere with a battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. The Company’s Inogen One systems reduce the patient’s reliance on stationary concentrators and scheduled deliveries of tanks with a finite supply of oxygen, thereby improving patient quality of life and fostering mobility.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company incorporated Inogen Europe Holding B.V., a Dutch limited liability company, on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 13, 2017</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. On May 4, 2017, Inogen Europe Holding B.V. acquired all issued and outstanding capital stock of MedSupport Systems B.V. (MedSupport) and began operating under the name Inogen Europe B.V. The Company merged Inogen Europe Holding B.V. and Inogen Europe B.V. on December 28, 2018. Inogen Europe B.V. is the remaining legal entity. Inogen completed the acquisition of New Aera, Inc. (New Aera) on August 9, 2019. On </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 14, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company completed the acquisition of all of the issued and outstanding capital stock of Physio-Assist SAS (Physio-Assist) and its wholly-owned subsidiary PhysioAssist GmbH.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1468000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1712000
CY2023	ingn	Allowance For Doubtful Accounts Receivable Current Percentage AllowanceForDoubtfulAccountsReceivableCurrentPercentage	0.063
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	560000
CY2022	ingn	Allowance For Doubtful Accounts Receivable Current Percentage AllowanceForDoubtfulAccountsReceivableCurrentPercentage	0.009
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition, warranty reserves and expense, determining the stand-alone selling price (SSP) and service period of performance obligations, rental asset valuations and write-downs, accounts receivable allowances for bad debts, returns and adjustments, impairment of goodwill, impairment of long-lived assets, stock-based compensation expense, income taxes, fair value of acquired intangible assets and goodwill, and fair value of earnout liabilities. Actual results could differ from these estimates.</span></p>
CY2023	ingn	Standard Warranty Period Offered StandardWarrantyPeriodOffered	P3Y
CY2023	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	6438000
CY2022	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	6598000
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	3219000
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	5156000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	251607000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	320549000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	311730000
CY2023Q4	ingn	Deferred Capped Rental Revenue DeferredCappedRentalRevenue	0
CY2022Q4	ingn	Deferred Capped Rental Revenue DeferredCappedRentalRevenue	0
CY2023	ingn	Rental Revenue Recognition New Accounting Pronouncement Timing RentalRevenueRecognitionNewAccountingPronouncementTiming	P30D
CY2023	us-gaap	Standard Product Warranty Description StandardProductWarrantyDescription	The Company generally provides a warranty against defects in material and workmanship. The Company provides a 3-year, 5-year or lifetime warranty on Inogen One systems and a 3-year and lifetime warranty on Inogen At Home systems sold. The Company only offers a lifetime warranty for direct-to-consumer sales of its oxygen concentrators.
CY2023	us-gaap	Derivatives Methods Of Accounting Hedging Derivatives DerivativesMethodsOfAccountingHedgingDerivatives	<p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair value of derivative instruments and hedging activities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company transacts business in foreign currencies and has international sales and expenses denominated in foreign currencies, subjecting the Company to foreign currency risk. The Company has entered into foreign currency forward contracts, generally with maturities of twelve months or less, to reduce the volatility of cash flows, primarily related to forecasted revenue denominated in certain foreign currencies. These contracts allow the Company to sell Euros in exchange for U.S. dollars at specified contract rates. Forward contracts are used to hedge forecasted sales over specific months. Changes in the fair value of these forward contracts designed as cash flow and balance sheet hedges are recorded as a component of accumulated other comprehensive income within stockholders’ equity and are recognized in the consolidated statements of comprehensive loss during the period which approximates the time the corresponding sales occur. The Company may also enter into foreign exchange contracts that are not designated as hedging instruments for financial accounting purposes. These contracts are generally entered into to offset the gains and losses on certain asset and liability balances until the expected time of repayment. Accordingly, any gains or losses resulting from changes in the fair value of the non-designated contracts are reported in other income (expense), net in the consolidated statements of comprehensive loss. The gains and losses on these contracts generally offset the gains and losses associated with the underlying foreign currency-denominated balances, which are also reported in other income (expense), net.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records the assets or liabilities associated with derivative instruments and hedging activities at fair value based on Level 2 inputs in other current assets or other current liabilities, respectively, in the consolidated balance sheets. The Company had a related payable of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">155</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">422</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company documents the hedging relationship and its risk management objective and strategy for undertaking the hedge, the hedging instrument, the hedged transaction, the nature of the risk being hedged, how the hedging instrument’s effectiveness in offsetting the hedged risk will be assessed prospectively and retrospectively, and a description of the method used to measure ineffectiveness. The Company assesses hedge effectiveness and ineffectiveness at a minimum quarterly but may assess it monthly. For derivative instruments that are designed and qualify as part of a cash flow hedging relationship, the effective portion of the gain or loss on the derivative is reported in other comprehensive loss and reclassified into earnings in the same periods during which the hedged transaction affects earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current period earnings.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company will discontinue hedge accounting prospectively when it determines that the derivative is no longer effective in offsetting cash flows attributable to the hedge risk. The cash flow hedge is de-designated because a forecasted transaction is not probable of occurring, or management determines to remove the designation of the cash flow hedge. In all situations in which hedge accounting is discontinued and the derivative remains outstanding, the Company continues to carry the derivative at its fair value on the balance sheets and recognizes any subsequent changes in the fair value in earnings. When it is probable that a forecasted transaction will not occur, the Company will discontinue hedge accounting and recognize immediately in earnings gains and losses that were accumulated in other comprehensive loss related to the hedging relationship.</span></p>
CY2023	ingn	Increase Decrease In Net Rental Revenue IncreaseDecreaseInNetRentalRevenue	1055000
CY2022	ingn	Increase Decrease In Net Rental Revenue IncreaseDecreaseInNetRentalRevenue	1483000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	42241000
CY2023	ingn	Health Care Organization Allowance For Doubtful Accounts Percentage Of Accounts Receivable Net HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivableNet	1.000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	62725000
CY2022	ingn	Health Care Organization Allowance For Doubtful Accounts Percentage Of Accounts Receivable Net HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivableNet	1.000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	42241000
CY2023	ingn	Health Care Organization Allowance For Doubtful Accounts Percentage Of Accounts Receivable Net HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivableNet	1.000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	62725000
CY2022	ingn	Health Care Organization Allowance For Doubtful Accounts Percentage Of Accounts Receivable Net HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivableNet	1.000
CY2023Q4	ingn	Doubtful Accounts DoubtfulAccounts	2341000
CY2023	ingn	Doubtful Accounts Percentage DoubtfulAccountsPercentage	0.052
CY2022Q4	ingn	Doubtful Accounts DoubtfulAccounts	77000
CY2022	ingn	Doubtful Accounts Percentage DoubtfulAccountsPercentage	0.001
CY2023Q4	ingn	Allowances For Sales Returns AllowancesForSalesReturns	479000
CY2023	ingn	Sales Returns Percentage SalesReturnsPercentage	0.011
CY2022Q4	ingn	Allowances For Sales Returns AllowancesForSalesReturns	483000
CY2022	ingn	Sales Returns Percentage SalesReturnsPercentage	0.008
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2820000
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of credit risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. At times, cash account balances may be in excess of the amounts insured by the Federal Deposit Insurance Corporation. However, management believes the risk of loss to be minimal. The Company performs periodic evaluations of the relative credit standing of these institutions and has not experienced any losses on its cash and cash equivalents to date. The Company has also entered into hedging relationships with a single counterparty to offset the forecasted Euro-based revenues. The credit risk has been reduced due to a net settlement arrangement whereby the Company is allowed to net settle transactions with a single net amount payable by one party to the other.</span></p>
CY2023	ingn	Percentage Of Non Us Revenue Invoiced In Euros PercentageOfNonUSRevenueInvoicedInEuros	0.777
CY2022	ingn	Percentage Of Non Us Revenue Invoiced In Euros PercentageOfNonUSRevenueInvoicedInEuros	0.709
CY2021	ingn	Percentage Of Non Us Revenue Invoiced In Euros PercentageOfNonUSRevenueInvoicedInEuros	0.741
CY2023	us-gaap	Revenues Revenues	315660000
CY2022	us-gaap	Revenues Revenues	377241000
CY2021	us-gaap	Revenues Revenues	358003000
CY2023	ingn	Transfer Of Inventory To Rental Equipment TransferOfInventoryToRentalEquipment	2187000
CY2022	ingn	Transfer Of Inventory To Rental Equipment TransferOfInventoryToRentalEquipment	1221000
CY2021	ingn	Transfer Of Inventory To Rental Equipment TransferOfInventoryToRentalEquipment	906000
CY2023Q4	us-gaap	Inventory Work In Process And Raw Materials InventoryWorkInProcessAndRawMaterials	18036000
CY2022Q4	us-gaap	Inventory Work In Process And Raw Materials InventoryWorkInProcessAndRawMaterials	26496000
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6871000
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	9324000
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3067000
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1727000
CY2023Q4	us-gaap	Inventory Net InventoryNet	21840000
CY2022Q4	us-gaap	Inventory Net InventoryNet	34093000
CY2023	ingn	Property Plant And Equipment Useful Life Term Description PropertyPlantAndEquipmentUsefulLifeTermDescription	Lesser of estimated useful life or remaining lease term
CY2023Q4	us-gaap	Property Plant And Equipment Salvage Value PropertyPlantAndEquipmentSalvageValue	0
CY2023	us-gaap	Cost Of Property Repairs And Maintenance CostOfPropertyRepairsAndMaintenance	5143000
CY2022	us-gaap	Cost Of Property Repairs And Maintenance CostOfPropertyRepairsAndMaintenance	4528000
CY2021	us-gaap	Cost Of Property Repairs And Maintenance CostOfPropertyRepairsAndMaintenance	3387000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	16950000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	15045000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	12853000
CY2023Q4	ingn	Rental Equipment Allowance RentalEquipmentAllowance	2606000
CY2022Q4	ingn	Rental Equipment Allowance RentalEquipmentAllowance	2255000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	98161000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	95113000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	47845000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	51844000
CY2023Q4	ingn	Rental Equipment Allowance RentalEquipmentAllowance	2606000
CY2022Q4	ingn	Rental Equipment Allowance RentalEquipmentAllowance	2255000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	50316000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	43269000
CY2022	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-52161000
CY2022Q4	ingn	Fair Value Of Earnout Benefit FairValueOfEarnoutBenefit	13687000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23176098
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22852571
CY2023	us-gaap	Advertising Expense AdvertisingExpense	27120000
CY2022	us-gaap	Advertising Expense AdvertisingExpense	33265000
CY2021	us-gaap	Advertising Expense AdvertisingExpense	35183000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22490027
CY2023	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	160682
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	115155
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-102449000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-83772000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-6333000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23176098
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22852571
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22490027
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23176098
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22852571
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22490027
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.42
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.67
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.42
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.67
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	166258
CY2023	ingn	Weighted Average Number Of Diluted Shares Outstanding Based On Net Loss WeightedAverageNumberOfDilutedSharesOutstandingBasedOnNetLoss	23336780
CY2022	ingn	Weighted Average Number Of Diluted Shares Outstanding Based On Net Loss WeightedAverageNumberOfDilutedSharesOutstandingBasedOnNetLoss	22967726
CY2021	ingn	Weighted Average Number Of Diluted Shares Outstanding Based On Net Loss WeightedAverageNumberOfDilutedSharesOutstandingBasedOnNetLoss	22656285
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1031540
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	857984
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	318581
CY2021Q4	us-gaap	Goodwill Goodwill	32979000
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	127000
CY2022Q4	us-gaap	Goodwill Goodwill	32852000
CY2023	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-344000
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	32894000
CY2023	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	9755000
CY2023Q4	us-gaap	Goodwill Goodwill	10057000
CY2023Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	32894000
CY2023Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	32894000
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1202000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8469000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8775000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	41680000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7089000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	34591000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6239000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6062000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	177000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	4026000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3978000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3846000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3731000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	3330000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	15680000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	34591000
CY2021	ingn	Rent Expense Including Short Term Lease Cost RentExpenseIncludingShortTermLeaseCost	4095000
CY2023Q3	us-gaap	Incentive From Lessor IncentiveFromLessor	395000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-83268000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	8659000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13454000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	18237000
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	10054000
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	10837000
CY2023Q4	ingn	Accrued Purchasing Card Liability AccruedPurchasingCardLiability	2197000
CY2022Q4	ingn	Accrued Purchasing Card Liability AccruedPurchasingCardLiability	2606000
CY2023Q4	ingn	Accrued Loss On Purchase Commitments AccruedLossOnPurchaseCommitments	2057000
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	472000
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	492000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1908000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1802000
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	30142000
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	33974000
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1110000
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	2620000
CY2023Q4	ingn	Accrued Wages And Other Payroll Related Items Current AccruedWagesAndOtherPayrollRelatedItemsCurrent	4170000
CY2022Q4	ingn	Accrued Wages And Other Payroll Related Items Current AccruedWagesAndOtherPayrollRelatedItemsCurrent	4967000
CY2023Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	3194000
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	3133000
CY2023Q4	ingn	Accrued Severance Current AccruedSeveranceCurrent	2284000
CY2023Q4	ingn	Accrued Employee Stock Purchase Plan Deductions AccruedEmployeeStockPurchasePlanDeductions	308000
CY2022Q4	ingn	Accrued Employee Stock Purchase Plan Deductions AccruedEmployeeStockPurchasePlanDeductions	470000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11066000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11190000
CY2023	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	options to extend the leases for up to 5 years.
CY2023	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2023	ingn	Rent Expense Including Short Term Lease Cost RentExpenseIncludingShortTermLeaseCost	4017000
CY2022	ingn	Rent Expense Including Short Term Lease Cost RentExpenseIncludingShortTermLeaseCost	3870000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	4044000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	3964000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	3979000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	3828000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1781000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	225000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.045
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.029
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths	4162000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Two LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo	3271000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Three LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree	3290000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Four LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour	3313000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive	2953000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive	6823000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	23812000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1889000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	21923000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3653000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	18270000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	21923000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-99015000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-84422000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	7621000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-3329000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	1154000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	1038000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-102344000
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	229000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	201000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	271000
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	127000
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	303000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	266000
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	356000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	504000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	537000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	10263000
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	4194000
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-251000
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-22000
CY2023	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-251000
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	14435000
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	20000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	105000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	504000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	14992000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	10121000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	10600000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	41195000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	27824000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	3015000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	2784000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5809000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4042000
CY2022Q4	ingn	Deferred Tax Assets Intangible Amortization DeferredTaxAssetsIntangibleAmortization	2045000
CY2023Q4	ingn	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	5098000
CY2022Q4	ingn	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	5674000
CY2023Q4	ingn	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	6257000
CY2022Q4	ingn	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	2915000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	71495000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	55884000
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	8806000
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	8674000
CY2023Q4	ingn	Deferred Tax Liabilities Intangible Amortization DeferredTaxLiabilitiesIntangibleAmortization	6528000
CY2023Q4	ingn	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	4732000
CY2022Q4	ingn	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	5277000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	20066000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	13951000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	59968000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	41933000
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	8539000
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P1Y4M9D
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0143
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0353
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0139
CY2023	ingn	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Expense Benefit EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationExpenseBenefit	-0.0066
CY2022	ingn	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Expense Benefit EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationExpenseBenefit	-0.0102
CY2021	ingn	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Expense Benefit EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationExpenseBenefit	-0.2172
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.0100
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.0132
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0595
CY2023	ingn	Effective Income Tax Rate Reconciliation Change In Fair Value EffectiveIncomeTaxRateReconciliationChangeInFairValue	0.0140
CY2022	ingn	Effective Income Tax Rate Reconciliation Change In Fair Value EffectiveIncomeTaxRateReconciliationChangeInFairValue	-0.0388
CY2021	ingn	Effective Income Tax Rate Reconciliation Change In Fair Value EffectiveIncomeTaxRateReconciliationChangeInFairValue	0.2819
CY2023	ingn	Effective Income Tax Rate Reconciliation Nondeductible Compensation EffectiveIncomeTaxRateReconciliationNondeductibleCompensation	-0.0009
CY2022	ingn	Effective Income Tax Rate Reconciliation Nondeductible Compensation EffectiveIncomeTaxRateReconciliationNondeductibleCompensation	-0.0150
CY2021	ingn	Effective Income Tax Rate Reconciliation Nondeductible Compensation EffectiveIncomeTaxRateReconciliationNondeductibleCompensation	0.0704
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1480
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2775
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	2.0169
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	-0.0675
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0017
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0007
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0063
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0010
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0061
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	1.7311
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	18035000
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	2778000
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	2366000
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	2078000
CY2021Q4	ingn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested And Exercisable Per Share Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedAndExercisablePerShareAverageIntrinsicValue	4.31
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	459441
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	42.18
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2366000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2078000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1932000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	400000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	242000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	146000
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	34000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	46000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	46000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2778000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2366000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2078000
CY2023	ingn	Voting Rights Associated With Each Share Of Common Stock VotingRightsAssociatedWithEachShareOfCommonStock	1
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	0
CY2022	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	0
CY2021	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	0
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	955479
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	35.49
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y10M6D
CY2020	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Per Share ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValuePerShare	11.81
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	486038
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	28.19
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	10000
CY2021	ingn	Share Based Compensation Arrangement By Share Based Payment Award Per Share Price Forfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardPerSharePriceForfeited	83.3
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	83.3
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	459441
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	42.18
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y4M9D
CY2021	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Per Share ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValuePerShare	4.31
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	459441
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	42.18
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P1Y4M9D
CY2021Q4	ingn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested And Expected To Vest Per Share Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedAndExpectedToVestPerShareAverageIntrinsicValue	4.31
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	459441
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	42.18
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y4M9D
CY2021	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Per Share ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValuePerShare	4.31
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	14154
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.14
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	15417
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	43.27
CY2022	ingn	Stock Issued During Period Shares Stock Options Expired StockIssuedDuringPeriodSharesStockOptionsExpired	81586
CY2022	ingn	Share Based Compensation Arrangements By Share Based Payment Award Options Expired In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice	40.08
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	348284
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	44.21
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P0Y5M4D
CY2022	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Per Share ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValuePerShare	2.07
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	348284
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	44.21
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P0Y5M4D
CY2022Q4	ingn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested And Exercisable Per Share Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedAndExercisablePerShareAverageIntrinsicValue	2.07
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	348284
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	44.21
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P0Y5M4D
CY2022Q4	ingn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested And Expected To Vest Per Share Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedAndExpectedToVestPerShareAverageIntrinsicValue	2.07
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	348284
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	44.21
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P0Y5M4D
CY2022	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Per Share ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValuePerShare	2.07
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	54432
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	7.03
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	6019
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	32.92
CY2023	ingn	Stock Issued During Period Shares Stock Options Expired StockIssuedDuringPeriodSharesStockOptionsExpired	267833
CY2023	ingn	Share Based Compensation Arrangements By Share Based Payment Award Options Expired In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice	49.1
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	20000
CY2023Q4	ingn	Share Based Compensation Arrangement By Share Based Payment Award Per Share Price Of Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardPerSharePriceOfShares	83.3
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	83.3
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P0Y4M9D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	20000
CY2023Q4	ingn	Share Based Compensation Arrangement By Share Based Payment Award Per Share Price Vested And Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardPerSharePriceVestedAndExercisable	83.3
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	83.3
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P0Y4M9D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	20000
CY2023Q4	ingn	Share Based Compensation Arrangement By Share Based Payment Award Per Share Price Vested And Expected To Vest ShareBasedCompensationArrangementByShareBasedPaymentAwardPerSharePriceVestedAndExpectedToVest	83.3
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	83.30
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P0Y4M9D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	735000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	309000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	14524000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7427000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12283000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10943000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7427000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12283000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10943000
CY2023Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	83000000
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	2057000
CY2022Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	19913000
CY2021Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	13726000
CY2020Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	14394000
CY2023	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	9843000
CY2022	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	10416000
CY2021	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	9168000
CY2023	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	5014000
CY2022	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	8234000
CY2021	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	-597000
CY2023	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	11292000
CY2022	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	12463000
CY2021	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	9239000
CY2023Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	23478000
CY2022Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	19913000
CY2021Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	13726000
CY2023	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	5014000
CY2023	us-gaap	Restructuring Costs RestructuringCosts	3426000
CY2023Q4	ingn	Accrued Liabilities Related To Restructuring Charges AccruedLiabilitiesRelatedToRestructuringCharges	638000
CY2023Q4	us-gaap	Derivative Remaining Maturity1 DerivativeRemainingMaturity1	P1M
CY2023	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-1140000
CY2021	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	1793000
CY2023Q4	ingn	Number Of Contract Ineffective Hedges NumberOfContractIneffectiveHedges	0
CY2022Q4	ingn	Number Of Contract Ineffective Hedges NumberOfContractIneffectiveHedges	3
CY2021Q4	ingn	Number Of Contract Ineffective Hedges NumberOfContractIneffectiveHedges	0
CY2023Q4	ingn	Number Of Contract Designated Hedges NumberOfContractDesignatedHedges	0
CY2023Q4	ingn	Number Of Contract Non Designated Hedges NumberOfContractNonDesignatedHedges	5
CY2022Q4	ingn	Number Of Contract Designated Hedges NumberOfContractDesignatedHedges	0
CY2022Q4	ingn	Number Of Contract Non Designated Hedges NumberOfContractNonDesignatedHedges	3

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0000950170-24-023820-index-headers.html	Edgar Link	pending
0000950170-24-023820-index.html	Edgar Link	pending
0000950170-24-023820.txt	Edgar Link	pending
0000950170-24-023820-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img252357023_0.jpg	Edgar Link	pending
ingn-20231231.htm	Edgar Link	pending
ingn-20231231.xsd	Edgar Link	pending
ingn-ex10_44.htm	Edgar Link	pending
ingn-ex10_45.htm	Edgar Link	pending
ingn-ex23_1.htm	Edgar Link	pending
ingn-ex31_1.htm	Edgar Link	pending
ingn-ex31_2.htm	Edgar Link	pending
ingn-ex32_1.htm	Edgar Link	pending
ingn-ex97_1.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
ingn-20231231_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INGN
Inogen Inc Stock $ingn

2024 Q1 Form 10-K Financial Statement

#000095017024023820 Filed on March 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INGN Inogen Inc Stock $ingn

2024 Q1 Form 10-K Financial Statement

#000095017024023820 Filed on March 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INGN
Inogen Inc Stock $ingn